HRT is Generally Safe with Ulcerative Colitis on Biologic Therapy
Hormone replacement therapy can be used in women with ulcerative colitis who are on biologic therapy, though there is a modest increased risk of UC flares that should be monitored. The decision should weigh menopausal symptom severity against potential disease activity, with closer monitoring during HRT initiation.
Evidence on HRT and UC Risk
The relationship between HRT and ulcerative colitis shows conflicting evidence:
A 2012 prospective cohort study found increased UC risk with postmenopausal hormone therapy (HR 1.71 for current users, 95% CI 1.07-2.74), with risk increasing with longer duration of use 1. This suggests estrogen pathways may influence UC pathogenesis.
However, a 2025 population-based study found no significant association between HRT use and IBD development (adjusted HR 1.33 for UC, 95% CI 0.46-3.83, p=0.600) over 11.1 years of follow-up 2. This more recent study suggests IBD risk may not be a primary concern when considering HRT.
The divergent findings likely reflect different study populations and methodologies, but the more recent large-scale study provides reassurance.
Safety of Biologics in UC
Biologics have well-established long-term safety profiles in UC patients 3, 4, 5. The 2020 AGA guidelines note that all approved biologics (infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab) were well-tolerated with low rates of serious adverse events not significantly different from placebo 3. Long-term safety data confirms no major new concerns emerge with extended use 4.
Practical Approach
When HRT is Appropriate:
- UC in stable remission on biologic therapy
- Significant menopausal symptoms affecting quality of life
- No recent flares or corticosteroid requirements
- Patient understands need for closer monitoring
Monitoring Strategy:
- Assess disease activity before HRT initiation - patients with active IBD are at higher risk of flare (58% vs 24%, p=0.003) 6
- Monitor for UC symptoms monthly for first 3-6 months after HRT start
- Maintain regular biologic therapy without interruption
- Consider fecal calprotectin monitoring every 3 months initially
- Have low threshold to escalate UC therapy if symptoms emerge
Key Caveats:
- Testosterone-based therapy may carry higher flare risk than estrogen (51% vs 26%, p=0.02) based on transgender patient data 6, though this may not directly translate to postmenopausal HRT
- The type of HRT (estrogen alone vs estrogen plus progestin) does not appear to differentially affect UC risk 1
- Risk appears to decrease after HRT discontinuation 1
When to Avoid or Delay HRT:
- Active UC flare or recent corticosteroid use within 3 months
- Inadequate response to current biologic therapy
- Planning to switch or escalate UC medications
- History of frequent flares despite biologic therapy
The biologic therapy itself should not be modified or interrupted when starting HRT - continue the established UC treatment regimen that has achieved disease control 3.